NASDAQ:PULM - Pulmatrix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.4878 0.00 (0.00 %)
(As of 07/22/2018 07:08 AM ET)
Previous Close$0.4878
Today's Range$0.47 - $0.50
52-Week Range$0.41 - $2.67
Volume283,411 shs
Average Volume1.17 million shs
Market Capitalization$19.63 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
Pulmatrix logoPulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Debt-to-Equity RatioN/A
Current Ratio0.33
Quick Ratio0.33

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$340,000.00
Price / Sales57.73
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book1.02

Profitability

EPS (Most Recent Fiscal Year)($0.93)
Net Income$-18,050,000.00
Net MarginsN/A
Return on Equity-171.39%
Return on Assets-109.20%

Miscellaneous

Employees24
Outstanding Shares40,240,000
Market Cap$19.63

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) released its earnings results on Friday, May, 11th. The biotechnology company reported ($0.24) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.09. The biotechnology company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.60 million. View Pulmatrix's Earnings History.

What price target have analysts set for PULM?

2 brokerages have issued 1 year price targets for Pulmatrix's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate Pulmatrix's stock price to reach $3.00 in the next year. This suggests a possible upside of 515.0% from the stock's current price. View Analyst Ratings for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest during the month of June. As of June 15th, there was short interest totalling 3,552,539 shares, an increase of 56.0% from the May 31st total of 2,276,808 shares. Based on an average daily volume of 3,647,979 shares, the short-interest ratio is currently 1.0 days. Currently, 10.7% of the shares of the stock are sold short. View Pulmatrix's Current Options Chain.

Who are some of Pulmatrix's key competitors?

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 49)
  • Mr. Teofilo David Raad, Chief Bus. Officer (Age 48)
  • Dr. James M. Roach, Chief Medical Officer (Age 58)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 69)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 57)

Has Pulmatrix been receiving favorable news coverage?

Press coverage about PULM stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pulmatrix earned a news sentiment score of 0.11 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 43.70 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $0.4878.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $19.63 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-18,050,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Pulmatrix employs 24 workers across the globe.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.